Innovation news

<p>Modesto Orozco during the award ceremony</p>
12 Dec 2019

Nostrum Biodiscoverya spin-off from IRB Barcelona and the BSC-CNS, focuses on computational simulation to design new drugs and biotech molecules for the market.

The Senén Vilaró Prize is given each year by the “Consejo Social” of the UB and the Bosch i Gimpera Foundation to the best innovative company.

30 Oct 2019

The Ministry of Science, Innovation and Universities, through the State Research Agency,  has awarded the Institute for Research in Biomedicine (IRB Barcelona) €237,500 to carry out the project “Fostering IRB Barcelona internationalisation and H2020 participation” (IRBInterH)”, an action supported by the  “Europa Redes y Gestores-Europa Centros Tecnológicos 2019” call (Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020).

The IRBInterH project will boost internationalisation, one of IRB Barcelona´s strategic goals. Likewise, it will also strengthen the participation of the institute in H2020, one of the key internationalization actions identified by the...

<p>Roger Gomis, head of the Growth Control and Cancer Metastasis Lab at IRB Barcelona and founder of Inbiomotion.</p>
15 Oct 2019

The economics newspaper Expansión Catalunya has echoed the forthcoming publication of the results of a clinical assay of the MAF-Test, a diagnostic test for breast cancer patients developed by Inbiomotion, a spin-off from IRB Barcelona set up in 2010 by the researcher Roger Gomis. The results are expected to be out in November. This test may have the capacity to identify those breast cancer patients who would benefit from treatment with bisphosphonates, a class of drugs used to treat non-metastatic breast cancer, but whose administration can in many cases be counterproductive. If the results are positive, it is hoped that this test will reduce mortality...

<p>Clara Campàs, founding partner of Asabys Partners, Salvador Aznar-Benitah and Valerie Vanhooren, founders of Ona Therapeutics, and Sergio Pérez, director of Sabadell Venture Capital</p>
22 Jul 2019

The weekly supplement Dinero of La Vanguardia has published an article about Ona Therapeutics, the spin-off created by IRB Barcelona, ICREA and the researchers Salvador Aznar-Benitah and Valerie Vanhooren, with funding from Sabadell Asabys. Based on results published by Aznar in the journal Nature in 2017, the company aims to find a new treatment for metastatic cancer. “We found that the cells that give rise to metastasis are “addicted” to fats, and we envisaged developing a product, an antibody, that can block the protein responsible for fat uptake in these cells and thus combat their proliferation,” explains the researcher.

16 Jul 2019

L’Econòmic, the weekly supplement if the local newspaper El Punt Avui, has pinpointed Ona Therapeutics, the new spin-off from IRB Barcelona, as one of the ten Catalan start-ups with greatest projection. The company, which was founded by IRB Barcelona, ICREA, and the researchers Salvador Aznar Benitah and Valerie Vanhooren, with funding from Sabadell Asabys, focuses on the development of a new drug for the treatment of metastatic cancer.

 

Link to L’Econòmic

7 Jun 2019

Israel Ramos is a drug discovery professional specialised in in vitro assay development support to research programs and compound characterisation. With his more than 15 years of experience in the pharmaceutical industry, he is currently working at the at IRB Barcelona Innovation department as Technology Transfer Consultant. Israel provides support to IRB Barcelona researchers by giving advice about the applicability of potential drug candidates based on IRB Barcelona discoveries.

“Pharma companies have changed their model of working, and now are more open to collaboration. They are...

<p>Clara Campàs, founding partner of Asabys Partners, Salvador Aznar-Benitah and Valerie Vanhooren, founders of Ona Therapeutics, and Sergio Pérez, director of Sabadell Venture Capital</p>
23 May 2019

La Vanguardia and Expansión Catalunya, among other media, have devoted an articleto Ona Therapeutics, the new IRB Barcelona spin-off that has completed a seed financing round of 1.5 million euros, invested entirely by Sabadell Asabys. With this injection of capital, the spin-off created by IRB Barcelona, ICREA and the researchers Salvador Aznar Benitah and Valerie Vanhooren, will start up activity with the development of a new drug for the treatment of metastatic cancer.

Link to La Vanguardia

Link to ...

22 May 2019

It is estimated that one in four people will require brain treatment at some point. While there are drug candidates for most diseases of the brain, the blood-brain barrier (BBB) poses an impassable obstacle for most of these compounds and a bottleneck for the delivery of drugs that could cure these patients.

In the Peptides and Proteins Lab at the Institute for Research in Biomedicine (IRB Barcelona), Dr. Meritxell Teixidó headsa line of research that, after 10 years, has led to the development of a technology called Gate2Brain. This patented technology consists of three...

<p>Clara Campàs, founding partner of Asabys Partners, Salvador Aznar-Benitah and Valerie Vanhooren, founders of Ona Therapeutics, and Sergio Pérez, director of Sabadell Venture Capital</p>
21 May 2019

Ona Therapeutics, a spin-off from IRB Barcelona and ICREA, has been founded by researchers Salvador Aznar-Benitah and Valerie Vanhooren after receiving investment from Sabadell Asabys.

Based at the Barcelona Science Park, the company focuses on the development of a new drug for the treatment of metastatic cancer.

The Sabadell Asabys Fund, which belongs to Asabys Partners, has invested € 1.5M into the company in order to start a venture round that could reach € 20M.

<p>Scheme of the intracellular processing of the 2shRNAs by the activity of Dicer enzyme, producing two independent fragments of shRNA, one against each target (M Terrazas, IRB Barcelona)</p>
21 Dec 2018

Modesto Orozco’s lab has published a paper in Chemical Communications about a therapeutic tool to prevent treatment resistance in breast cancer.

The tool has been tested in tumour cells in vitro and will now need to be tested in animal models before moving on to the development of a valid treatment for patients.